Key Takeaways BEAM and NTLA are compared as gene editing biotechs with pipelines at different development stages.BEAM advances multiple SCD programs and updates its BEAM-101 and BEAM-301 studies across phases.NTLA pushes late-stage in vivo candidates while a clinical hold on nex-z raises safety concerns.Beam Therapeutics (BEAM) and Intellia Therapeutics (NTLA) are clinical-stage companies developing investigational gene therapies. While BEAM’s pipeline candidates are still in early-stage development, NTLA i ...

We recently published 10 Best Small-Cap Stocks With Huge Potential According to Reddit as Market Looks Beyond AI Trade. Halozyme Therapeutics, Inc. (NASDAQ:HALO) is among the best small-cap stocks to buy according to Redditors. Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best small-cap stocks with huge upside potential according to Redditors. The company is working on oncology therapies designed to target the tumor microenvironment. The company recently announced to acquire Elektrofi, which ca ...

Recognizes the company’s continued investment and expansion of cell therapy manufacturing and R&D operations in Ghent, reinforcing Flanders’ position as a global biotech hub SOMERSET, N.J. and GHENT, Belgium, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that the Company has been awarded Foreign Investor of the Year at the 2025 Flanders International Business Awards (FIBA) hosted by Flanders Investment & Trade ( ...

The mid-cap biotech could become a notable player in the industry's hottest therapeutic area.Novo Nordisk (NVO +3.51%), a Denmark-based drugmaker, is currently a leader in the rapidly growing weight loss market. The company's Wegovy has practically become a household name, and it has plenty more pipeline candidates in the works.However, this area is attracting many more challengers looking to capitalize on its fast expansion. One of them is Viking Therapeutics (VKTX +2.34%), a mid-cap biotech. This smaller ...

Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces its intention to undertake a non-brokered private placement offering (the “Offering”) of up to 16 million common shares (“Shares”) at a price of $0.05 per Share for gross proceeds of up to $800,000. The net proceeds of the Offering will be used for working capital and general corpora ...

Prediction: Vertex will be much larger by the end of the decade.A lot can change in five years. Take Vertex Pharmaceuticals (VRTX +0.55%), for example. In late 2020, the big biotech company's approved products focused on one indication – cystic fibrosis (CF). And Vertex's market cap was nearly half what it is today.It's reasonable to assume that much will change for the company by 2030 as well. Where will Vertex Pharmaceuticals be in five years? Here's my best guess. What will remain the same for VertexI ex ...

Incyte Corporation ( INCY ) is a profitable late‑stage biotech firm with ~$20 billion in market cap. As far as I can see, INCY's revenue and earnings base keeps diversifying, and while the market has already repriced the stock price toA seasoned consulting specialist at a leading Central Asian bank. The author behind Novo Capital brings half a decade of experience delivering strategic insight and analysis for the bank's clientele within the private banking branch. Launching the career back in 2020 after gra ...

Edison Issues Report on Percheron Therapeutics (PER)November 27, 2025 3:16 AM EST | Source: Edison GroupLondon, United Kingdom--(Newsfile Corp. - November 27, 2025) - Edison issues report on Percheron Therapeutics (ASX: PER)We have refreshed our investment case for Percheron as the company heads into CY26 with a clearly defined Phase II plan for HMBD-002, backed by positive Phase I data and a strengthened management team. Our model now reflects the likely Phase II basket design, comprising exp ...

中信建投（601066）发布研报称，2025年，核心产品泰它西普新增适应症获批后快速放量，维迪西妥单 抗联合治疗方案数据优异，同时RC28的DME适应症上市申请获受理；在研管线中RC148获突破性疗法 认定，临床数据持续验证价值。整体看，公司商业化进程提速，管线梯队布局完善，看好公司后续发 展。 荣昌生物(09995)午后涨超7%，截至发稿，涨6.39%，报90.75港元，成交额3.19亿港元。 消息面上，据公众号，2025年ESMO年会上，维迪西妥单抗联合特瑞普利单抗对比化疗一线治疗HER2 表达的局部晚期或转移性尿路上皮癌Ⅲ期临床研究发布。甬兴证券发布研报称，维迪西妥联合免疫疗效 优异，标志着尿路上皮癌治疗格局重大变革。 ...

Core Viewpoint - Rosen Law Firm is encouraging investors of Skye Bioscience, Inc. to secure legal counsel before the January 16, 2026 deadline for lead plaintiff applications in a securities class action lawsuit [1][3]. Group 1: Class Action Details - Investors who purchased Skye securities between November 4, 2024, and October 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [3][5]. - The lawsuit alleges that defendants made materially false and misleading statements regarding Skye's business and the effectiveness of its product, nimacimab, which led to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Many attorneys at Rosen Law Firm have received recognition from Lawdragon and Super Lawyers, emphasizing the firm's expertise in this area [4].